Literature DB >> 6284519

Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

P J McNamara, K Stoeckel, W H Ziegler.   

Abstract

The pharmacokinetic parameters of total (bound and unbound) and free (unbound) ceftriaxone in six healthy volunteers after intravenous injection of 39 were compared with low-dose data from a previous study. The dose-dependent behaviour of total drug was considerably more pronounced after the 3 gram dose. In contrast, total body clearance (C1FS = 258 ml/Min), renal clearance (C1FR = 170 ml/min) and volume of distribution (VFD (beta) = 168 1) of free (unbound) drug did not differ from the data reported earlier. There was no significant change in biological half-life (t1/2 (beta) = 7.8 h) or in the fraction excreted unchanged in urine (fu = 0.67).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284519     DOI: 10.1007/bf00606428

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

Review 1.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Comparative pharmacokinetics of cefoperazone and cefotaxime.

Authors:  H Lode; B Kemmerich; P Koeppe; D Belmega; H Jendroschek
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

3.  Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.

Authors:  R Wise; S Baker; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

4.  Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.

Authors:  R Reiner; U Weiss; U Brombacher; P Lanz; M Montavon; A Furlenmeier; P Angehrn; P J Probst
Journal:  J Antibiot (Tokyo)       Date:  1980-07       Impact factor: 2.649

5.  Single-dose pharmacokinetics of cefoperazone following intravenous administration.

Authors:  W A Craig
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

6.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

7.  [Pharmacokinetics of a new cephalosporin, cefoperazone].

Authors:  A F Allaz; P Dayer; J Fabre; M Rudhardt; L Balant
Journal:  Schweiz Med Wochenschr       Date:  1979-12-29

8.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

9.  Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Authors:  K Stoeckel; P J McNamara; R Brandt; H Plozza-Nottebrock; W H Ziegler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

  9 in total
  27 in total

1.  Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis.

Authors:  Sendia Kim; Kathleen M Gura; Mark Puder
Journal:  Pediatr Surg Int       Date:  2006-02-17       Impact factor: 1.827

2.  Dose-dependent pharmacokinetics of L-693,612, a carbonic anhydrase inhibitor, following oral administration in rats.

Authors:  B K Wong; P J Bruhin; J H Lin
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

3.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.

Authors:  I H Patel; J G Sugihara; R E Weinfeld; E G Wong; A W Siemsen; S J Berman
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

Review 5.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Characteristics of ceftriaxone binding to immunoglobulin G and potential clinical significance.

Authors:  H Sun; M S Chow; E G Maderazo
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

7.  Pharmacokinetics and protein binding of ceftriaxone during pregnancy.

Authors:  P Bourget; H Fernandez; V Quinquis; C Delouis
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.

Authors:  W L Hayton; R Schandlik; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Acute cholecystitis caused by ceftriaxone stones in an adult.

Authors:  Christian D Becker; Robert A Fischer
Journal:  Case Rep Med       Date:  2009-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.